HSC
HARSCO CORP
stock NYSE

Artelo Biosciences (ARTL) absolutely ripped today off a catalyst that's been building for the past couple weeks.
\*\***The catalyst**\*\*
Artelo announced an agreement for a fully-funded clinical study evaluating ART27.13's efficacy in glaucoma patients. The study is funded externally by Glaucoma UK and the HSC R&D Division, with participant enrollment expected in Q2 2026. This is Artelo's first move into ophthalmology and first externally-funded clinical agreement — the glaucoma market is estimated at $16.3B.
\*\***Why ARTL specifically**\*\*
This is a sub-$3M market cap biotech with a 705K share float. When a company this small gets a legitimate clinical catalyst with external funding, the supply/demand imbalance is extreme. The external funding angle is key — it means no dilution to shareholders for this trial, which is rare for a micro-cap biotech.
\*\***The numbers**\*\*
\- Market cap: \~$2.3M
\- Float: 705K shares
\- Day volume: 2.1M (1.71x average daily volume of 1.25M)
\- Prev close: $3.19
\- Gap: +6.9%
\- Short ratio: 1.43
\- 52-week range: $2.96 – $85.80 (96% below 52-week high)
The float turnover here was nearly 3x — 2.1M shares traded on a 705K float. That's the kind of churn that creates these parabolic moves.
\*\***Signal timing**\*\*
Stock Pulse sent me a push notification at 8:17 AM at $6.46. It peaked at $19.91 around 12:34 PM — about 4 hours later. +208%.
\*\***Bear case**\*\*
\- Closed at $8.43, a massive fade from the $19.91 peak — classic low-float blowoff top
\- ART27.13 is still very early stage with no efficacy data yet
\- Company is down 96% from its 52-week high of $85.80 for a reason — history of dilution and failed catalysts
\- Micro-cap biotechs regularly gap up on study announcements and give it all back within days
\- External funding sounds good, but the study hasn't started and enrollment is months away
https://preview.redd.it/rg0zwgoeqnrg1.png?width=2779&format=png&auto=webp&s=e37567afa76317b61e5793ad0ac244a0ac65fa83

Artelo Biosciences (ARTL) absolutely ripped today off a catalyst that's been building for the past couple weeks.
\*\***The catalyst**\*\*
Artelo announced an agreement for a fully-funded clinical study evaluating ART27.13's efficacy in glaucoma patients. The study is funded externally by Glaucoma UK and the HSC R&D Division, with participant enrollment expected in Q2 2026. This is Artelo's first move into ophthalmology and first externally-funded clinical agreement — the glaucoma market is estimated at $16.3B.
\*\***Why ARTL specifically**\*\*
This is a sub-$3M market cap biotech with a 705K share float. When a company this small gets a legitimate clinical catalyst with external funding, the supply/demand imbalance is extreme. The external funding angle is key — it means no dilution to shareholders for this trial, which is rare for a micro-cap biotech.
\*\***The numbers**\*\*
\- Market cap: \~$2.3M
\- Float: 705K shares
\- Day volume: 2.1M (1.71x average daily volume of 1.25M)
\- Prev close: $3.19
\- Gap: +6.9%
\- Short ratio: 1.43
\- 52-week range: $2.96 – $85.80 (96% below 52-week high)
The float turnover here was nearly 3x — 2.1M shares traded on a 705K float. That's the kind of churn that creates these parabolic moves.
\*\***Signal timing**\*\*
Stock Pulse sent me a push notification at 8:17 AM at $6.46. It peaked at $19.91 around 12:34 PM — about 4 hours later. +208%.
\*\***Bear case**\*\*
\- Closed at $8.43, a massive fade from the $19.91 peak — classic low-float blowoff top
\- ART27.13 is still very early stage with no efficacy data yet
\- Company is down 96% from its 52-week high of $85.80 for a reason — history of dilution and failed catalysts
\- Micro-cap biotechs regularly gap up on study announcements and give it all back within days
\- External funding sounds good, but the study hasn't started and enrollment is months away
https://preview.redd.it/tnr5l3pdpnrg1.png?width=2779&format=png&auto=webp&s=11065356347e8e061c5358f704416df8b109fb82

Artelo Biosciences (ARTL) absolutely ripped today off a catalyst that's been building for the past couple weeks.
\*\***The catalyst**\*\*
Artelo announced an agreement for a fully-funded clinical study evaluating ART27.13's efficacy in glaucoma patients. The study is funded externally by Glaucoma UK and the HSC R&D Division, with participant enrollment expected in Q2 2026. This is Artelo's first move into ophthalmology and first externally-funded clinical agreement — the glaucoma market is estimated at $16.3B.
\*\***Why ARTL specifically**\*\*
This is a sub-$3M market cap biotech with a 705K share float. When a company this small gets a legitimate clinical catalyst with external funding, the supply/demand imbalance is extreme. The external funding angle is key — it means no dilution to shareholders for this trial, which is rare for a micro-cap biotech.
\*\***The numbers**\*\*
\- Market cap: \~$2.3M
\- Float: 705K shares
\- Day volume: 2.1M (1.71x average daily volume of 1.25M)
\- Prev close: $3.19
\- Gap: +6.9%
\- Short ratio: 1.43
\- 52-week range: $2.96 – $85.80 (96% below 52-week high)
The float turnover here was nearly 3x — 2.1M shares traded on a 705K float. That's the kind of churn that creates these parabolic moves.
\*\***Signal timing**\*\*
Stock Pulse sent me a push notification at 8:17 AM at $6.46. It peaked at $19.91 around 12:34 PM — about 4 hours later. +208%.
\*\***Bear case**\*\*
\- Closed at $8.43, a massive fade from the $19.91 peak — classic low-float blowoff top
\- ART27.13 is still very early stage with no efficacy data yet
\- Company is down 96% from its 52-week high of $85.80 for a reason — history of dilution and failed catalysts
\- Micro-cap biotechs regularly gap up on study announcements and give it all back within days
\- External funding sounds good, but the study hasn't started and enrollment is months away
https://preview.redd.it/rg0zwgoeqnrg1.png?width=2779&format=png&auto=webp&s=e37567afa76317b61e5793ad0ac244a0ac65fa83

Artelo Biosciences (ARTL) absolutely ripped today off a catalyst that's been building for the past couple weeks.
\*\***The catalyst**\*\*
Artelo announced an agreement for a fully-funded clinical study evaluating ART27.13's efficacy in glaucoma patients. The study is funded externally by Glaucoma UK and the HSC R&D Division, with participant enrollment expected in Q2 2026. This is Artelo's first move into ophthalmology and first externally-funded clinical agreement — the glaucoma market is estimated at $16.3B.
\*\***Why ARTL specifically**\*\*
This is a sub-$3M market cap biotech with a 705K share float. When a company this small gets a legitimate clinical catalyst with external funding, the supply/demand imbalance is extreme. The external funding angle is key — it means no dilution to shareholders for this trial, which is rare for a micro-cap biotech.
\*\***The numbers**\*\*
\- Market cap: \~$2.3M
\- Float: 705K shares
\- Day volume: 2.1M (1.71x average daily volume of 1.25M)
\- Prev close: $3.19
\- Gap: +6.9%
\- Short ratio: 1.43
\- 52-week range: $2.96 – $85.80 (96% below 52-week high)
The float turnover here was nearly 3x — 2.1M shares traded on a 705K float. That's the kind of churn that creates these parabolic moves.
\*\***Signal timing**\*\*
Stock Pulse sent me a push notification at 8:17 AM at $6.46. It peaked at $19.91 around 12:34 PM — about 4 hours later. +208%.
\*\***Bear case**\*\*
\- Closed at $8.43, a massive fade from the $19.91 peak — classic low-float blowoff top
\- ART27.13 is still very early stage with no efficacy data yet
\- Company is down 96% from its 52-week high of $85.80 for a reason — history of dilution and failed catalysts
\- Micro-cap biotechs regularly gap up on study announcements and give it all back within days
\- External funding sounds good, but the study hasn't started and enrollment is months away
https://preview.redd.it/tnr5l3pdpnrg1.png?width=2779&format=png&auto=webp&s=11065356347e8e061c5358f704416df8b109fb82